Advertisement

Relation of Elevated Serum Uric Acid Levels to Incidence of Atrial Fibrillation in Patients With Type 2 Diabetes Mellitus

      The association between serum uric acid (SUA) levels and atrial fibrillation (AF) is currently poorly known. We examined the association between SUA levels and risk of incident AF in patients with type 2 diabetes mellitus. We followed for 10 years a random sample of 400 type 2 diabetic outpatients, who were free from AF at baseline. A standard 12-lead electrocardiography was undertaken annually and a diagnosis of incident AF was confirmed in affected participants by a single cardiologist. Over 10 years, there were 42 incident AF cases (cumulative incidence of 10.5%). Elevated SUA level was associated with an increased risk of incident AF (odds ratio 2.43, 95% confidence interval 1.8 to 3.4, p <0.0001 for each 1-SD increase in SUA level). Adjustments for age, gender, body mass index, hypertension, chronic kidney disease, electrocardiographic features (left ventricular hypertrophy and PR interval), and use of diuretics and allopurinol did not attenuate the association between SUA and incident AF (adjusted odds ratio 2.44, 95% confidence interval 1.6 to 3.9, p <0.0001). Further adjustment for variables that were included in the 10-year Framingham Heart Study–derived AF risk score did not appreciably weaken this association. Results remained unchanged even when SUA was modeled as a categorical variable (stratifying by either SUA median or hyperuricemia), and when patients with previous coronary heart disease or heart failure were excluded from analysis. In conclusion, our findings suggest that elevated SUA levels are strongly associated with an increased incidence of AF in patients with type 2 diabetes mellitus even after adjustment for multiple clinical risk factors for AF.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to American Journal of Cardiology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Feig D.I.
        • Kang D.H.
        • Johnson R.J.
        Uric acid and cardiovascular risk.
        N Engl J Med. 2008; 359: 1811-1821
        • Lippi G.
        • Montagnana M.
        • Franchini M.
        • Favaloro E.J.
        • Targher G.
        The paradoxical relationship between serum uric acid and cardiovascular disease.
        Clin Chim Acta. 2008; 392: 1-7
        • Hoeper M.M.
        • Hohlfeld J.M.
        • Fabel H.
        Hyperuricaemia in patients with right or left heart failure.
        Eur Respir J. 1999; 13: 682-685
        • Chrysohoou C.
        • Pitsavos C.
        • Barbetseas J.
        • Brili S.
        • Kotroyiannis I.
        • Papademetriou L.
        • Metallinos G.
        • Skoumas J.
        • Tentolouris C.
        • Stefanadis C.
        Serum uric acid levels correlate with left atrial function and systolic right ventricular function in patients with newly diagnosed heart failure: the hellenic heart failure study.
        Congest Heart Fail. 2008; 14: 229-233
        • Letsas K.P.
        • Korantzopoulos P.
        • Filippatos G.S.
        • Mihas C.C.
        • Markou V.
        • Gavrielatos G.
        • Efremidis M.
        • Sideris A.
        • Kardaras F.
        Uric acid elevation in atrial fibrillation.
        Hellenic J Cardiol. 2010; 51: 209-213
        • Liu T.
        • Zhang X.
        • Korantzopoulos P.
        • Wang S.
        • Li G.
        Uric acid levels and atrial fibrillation in hypertensive patients.
        Intern Med. 2011; 50: 799-803
        • Liu Y.
        • Liu H.
        • Dong L.
        • Chen J.
        • Guo J.
        Prevalence of atrial fibrillation in hospitalized patients over 40 years old: ten-year data from the People's Hospital of Peking University.
        Acta Cardiol. 2010; 65: 221-224
        • Suzuki S.
        • Sagara K.
        • Otsuka T.
        • Matsuno S.
        • Funada R.
        • Uejima T.
        • Oikawa Y.
        • Koike A.
        • Nagashima K.
        • Kirigaya H.
        • Yajima J.
        • Sawada H.
        • Aizawa T.
        • Yamashita T.
        Gender-specific relationship between serum uric acid level and atrial fibrillation prevalence.
        Circ J. 2012; 76: 607-611
        • Tamariz L.
        • Agarwal S.
        • Soliman E.Z.
        • Chamberlain A.M.
        • Prineas R.
        • Folsom A.R.
        • Ambrose M.
        • Alonso A.
        Association of serum uric acid with incident atrial fibrillation (from the Atherosclerosis Risk In Communities [ARIC] study).
        Am J Cardiol. 2011; 108: 1272-1276
        • Letsas K.P.
        • Siklódy C.H.
        • Korantzopoulos P.
        • Weber R.
        • Bürkle G.
        • Mihas C.C.
        • Kalusche D.
        • Arentz T.
        The impact of body mass index on the efficacy and safety of catheter ablation of atrial fibrillation.
        Int J Cardiol. 2013; 164: 94-98
        • He X.N.
        • Li S.N.
        • Zhan J.L.
        • Xie S.L.
        • Zhang Z.J.
        • Dong J.Z.
        • Yu R.H.
        • Long D.Y.
        • Tang R.B.
        • Ma C.S.
        Serum uric acid levels correlate with recurrence of paroxysmal atrial fibrillation after catheter ablation.
        Chin Med J (Engl). 2013; 126: 860-864
        • Nichols G.A.
        • Reinier K.
        • Chugh S.S.
        Independent contribution of diabetes to increased prevalence and incidence of atrial fibrillation.
        Diabetes Care. 2009; 32: 1851-1856
        • Vanezis A.P.
        • Bhopal R.
        Validity of electrocardiographic classification of left ventricular hypertrophy across adult ethnic groups with echocardiography as a standard.
        J Electrocardiol. 2008; 41: 404-412
        • Stevens L.A.
        • Coresh J.
        • Greene T.
        • Levey A.S.
        Assessing kidney function—measured and estimated glomerular filtration rate.
        N Engl J Med. 2006; 354: 2473-2483
        • Schnabel R.B.
        • Sullivan L.M.
        • Levy D.
        • Pencina M.J.
        • Massaro J.M.
        • D'Agostino Sr., R.B.
        • Newton-Cheh C.
        • Yamamoto J.F.
        • Magnani J.W.
        • Tadros T.M.
        • Kannel W.B.
        • Wang T.J.
        • Ellinor P.T.
        • Wolf P.A.
        • Vasan R.S.
        • Benjamin E.J.
        Development of a risk score for atrial fibrillation (Framingham Heart Study): a community-based cohort study.
        Lancet. 2009; 373: 739-745
        • Jalal D.I.
        • Chonchol M.
        • Chen W.
        • Targher G.
        Uric acid as a target of therapy in chronic kidney disease.
        Am J Kidney Dis. 2013; 61: 134-146
        • Zhao Q.Y.
        • Yu S.B.
        • Huang H.
        • Cui H.Y.
        • Qin M.
        • Huang T.
        • Huang C.X.
        Serum uric acid levels correlate with atrial fibrillation in patients with chronic systolic heart failure.
        Chin Med J (Engl). 2012; 125: 1708-1712
        • Lip G.Y.
        • Tse H.F.
        • Lane D.A.
        Atrial fibrillation.
        Lancet. 2012; 379: 648-661
        • Chamberlain A.M.
        • Agarwal S.K.
        • Folsom A.R.
        • Soliman E.Z.
        • Chambless L.E.
        • Crow R.
        • Ambrose M.
        • Alonso A.
        A clinical risk score for atrial fibrillation in a biracial prospective cohort (from the Atherosclerosis Risk in Communities [ARIC] study).
        Am J Cardiol. 2011; 107: 85-91
        • Aviles R.J.
        • Martin D.O.
        • Apperson-Hansen C.
        • Houghtaling P.L.
        • Rautaharju P.
        • Kronmal R.A.
        • Tracy R.P.
        • Van Wagoner D.R.
        • Psaty B.M.
        • Lauer M.S.
        • Chung M.K.
        Inflammation as a risk factor for atrial fibrillation.
        Circulation. 2003; 108: 3006-3010
        • Guo Y.
        • Lip G.Y.
        • Apostolakis S.
        Inflammation in atrial fibrillation.
        J Am Coll Cardiol. 2012; 60: 2263-2270
        • Dudley Jr., S.C.
        • Hoch N.E.
        • McCann L.A.
        • Honeycutt C.
        • Diamandopoulos L.
        • Fukai T.
        • Harrison D.G.
        • Dikalov S.I.
        • Langberg J.
        Atrial fibrillation increases production of superoxide by the left atrium and left atrial appendage: role of the NADPH and xanthine oxidases.
        Circulation. 2005; 112: 1266-1273
        • Mihm M.J.
        • Yu F.
        • Carnes C.A.
        • Reiser P.J.
        • McCarthy P.M.
        • Van Wagoner D.R.
        • Bauer J.A.
        Impaired myofibrillar energetics and oxidative injury during human atrial fibrillation.
        Circulation. 2011; 104: 174-180
        • Kang D.H.
        • Han L.
        • Ouyang X.
        • Kahn A.M.
        • Kanellis J.
        • Li P.
        • Feng L.
        • Nakagawa T.
        • Watanabe S.
        • Hosoyamada M.
        • Endou H.
        • Lipkowitz M.
        • Abramson R.
        • Mu W.
        • Johnson R.J.
        Uric acid causes vascular smooth muscle cell proliferation by entering cells via a functional urate transporter.
        Am J Nephrol. 2005; 25: 425-433
        • Kanellis J.
        • Watanabe S.
        • Li J.H.
        • Kang D.H.
        • Li P.
        • Nakagawa T.
        • Wamsley A.
        • Sheikh-Hamad D.
        • Lan H.Y.
        • Feng L.
        • Johnson R.J.
        Uric acid stimulates monocyte chemoattractant protein-1 production in vascular smooth muscle cells via mitogen-activated protein kinase and cyclooxygenase-2.
        Hypertension. 2003; 41: 1287-1293
        • Baldwin W.
        • McRae S.
        • Marek G.
        • Wymer D.
        • Pannu V.
        • Baylis C.
        • Johnson R.J.
        • Sautin Y.Y.
        Hyperuricemia as a mediator of the proinflammatory endocrine imbalance in the adipose tissue in a murine model of the metabolic syndrome.
        Diabetes. 2011; 60: 1258-1269
        • Mercuro G.
        • Vitale C.
        • Cerquetani E.
        • Zoncu S.
        • Deidda M.
        • Fini M.
        • Rosano G.M.
        Effect of hyperuricaemia upon endothelial function in patients at increased cardiovascular risk.
        Am J Cardiol. 2004; 94: 932-935
        • Butler R.
        • Morris A.D.
        • Belch J.J.
        • Hill A.
        • Struthers A.D.
        Allopurinol normalizes endothelial dysfunction in type 2 diabetics with mild hypertension.
        Hypertension. 2000; 35: 746-751
        • Rajendra N.S.
        • Ireland S.
        • George J.
        • Belch J.J.
        • Lang C.C.
        • Struthers A.D.
        Mechanistic insights into the therapeutic use of high-dose allopurinol in angina pectoris.
        J Am Coll Cardiol. 2011; 58: 820-828
        • Doehner W.
        • Schoene N.
        • Rauchhaus M.
        • Leyva-Leon F.
        • Pavitt D.V.
        • Reaveley D.A.
        • Schuler G.
        • Coats A.J.
        • Anker S.D.
        • Hambrecht R.
        Effects of xanthine oxidase inhibition with allopurinol on endothelial function and peripheral blood flow in hyperuricemic patients with chronic heart failure: results from 2 placebo-controlled studies.
        Circulation. 2002; 105: 2619-2624